Olbrich H G, Hopf R, Klepzig H, Hör G, Maul F D, Kaltenbach M
Abteilung für Kardiologie, Johann Wolfgang Goethe-Universität, Frankfurt am Main.
Z Kardiol. 1989;78 Suppl 5:29-35.
Left ventricular function was investigated by radionuclide ventriculography in 13 patients (11 male, two female) with hypertrophic cardiomyopathy, aged from 22-57 years (mean 45.5 years) at rest and during exercise. Ten patients had hypertrophic obstructive cardiomyopathy with maximal left ventricular outflow tract gradients of 64-290 mmHg (mean 147 mmHg). Left ventricular enddiastolic pressure of all patients ranged from 8-35 mmHg (mean 21 mmHg). Radionuclide ventriculography was performed without therapy, after acute application of a single oral dose of gallopamil (50 mg), and after longterm treatment for 3 weeks (50 mg tid). Ejection fraction at rest after single dose increased from 69.2% to 72.9% (p less than 0.02), peak ejection rate (PER) increased from 333.5 to 362.0/s (p less than 0.01) and peak filling rate (PFR) from 284.5 to 316.5/s (p less than 0.02). Under exercise single dose as well as longterm treatment led to a slight but significant shift in the ratio of PFR/PER (from 1.02 to 1.12 after single dose [p less than 0.04], and to 1.18 with longterm treatment [p less than 0.03]). There was no correlation between the individual response to gallopamil treatment and histopathological parameters such as hypertrophy or fibrosis. These data demonstrate that gallopamil in patients with hypertrophic cardiomyopathy leads to an improvement mainly in left ventricular diastolic function which appears to be most effective under exercise.
对13例肥厚型心肌病患者（11例男性，2例女性）进行了放射性核素心室造影，以研究静息和运动时的左心室功能。患者年龄在22至57岁之间（平均45.5岁）。10例患者为肥厚型梗阻性心肌病，左心室流出道最大压力阶差为64至290 mmHg（平均147 mmHg）。所有患者的左心室舒张末期压力范围为8至35 mmHg（平均21 mmHg）。在未治疗时、单次口服加洛帕米（50 mg）后以及长期治疗3周（50 mg，每日3次）后进行放射性核素心室造影。单次给药后静息时射血分数从69.2%增加到72.9%（p<0.02），峰值射血率（PER）从333.5增加到362.0/s（p<0.01），峰值充盈率（PFR）从284.5增加到316.5/s（p<0.02）。运动时，单次给药以及长期治疗均导致PFR/PER比值略有但显著变化（单次给药后从1.02变为1.12 [p<0.04]，长期治疗后变为1.18 [p<0.03]）。加洛帕米治疗的个体反应与组织病理学参数如肥厚或纤维化之间无相关性。这些数据表明，加洛帕米对肥厚型心肌病患者主要改善左心室舒张功能，运动时似乎最有效。
